Literature DB >> 2674990

Weekly epirubicin in patients with hormone refractory prostatic cancer--a two-year follow-up.

K Burk1, W Schultze-Seemann, D Jonas, G Rodeck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2674990

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN： 0361-7742


× No keyword cloud information.
  2 in total

Review 1.  Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer.

Authors:  C Anderström
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life.

Authors:  G van Andel; P Fernandez de Moral; C T M Caris; P Carpentier; J Wils; M J F M de Bruin; J A Witjes; F M J Debruyne; W P J Witjes
Journal:  World J Urol       Date:  2003-06-18       Impact factor: 4.226
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.